Composite Indices Using 3 or 4 Components of the Core Data Set Have Similar Predictive Ability to Measure Disease Activity in RA: Evidence from the DANCER and REFLEX Studies
Table 2
Treatment comparisons of changes from baseline in composite indices by number of components and RA Core Data Set measures.
Components
Number of components
REFLEX
DANCER
SRM
value
SRM
value
SJC, DOCGL, FN, CRP
4
1.13
0.85
SJC, PATGL, DOCGL, CRP
4
1.13
0.86
SJC, PAIN, DOCGL, CRP
4
1.12
0.84
SJC, PATGL, FN, CRP
4
1.09
0.82
SJC, PAIN, FN, CRP
4
1.09
0.81
TJC, DOCGL, FN, CRP
4
1.10
0.81
PATGL, DOCGL, FN, CRP
4
1.09
0.83
PAIN, DOCGL, FN, CRP
4
1.09
0.82
TJC, PAIN, DOCGL, CRP
4
1.09
0.80
TJC, PATGL, DOCGL, CRP
4
1.10
0.81
SJC, TJC, FN, CRP
4
1.07
0.77
SJC, TJC, PATGL, CRP
4
1.07
0.79
SJC, TJC, DOCGL, CRP
4
1.08
0.80
SJC, TJC, PAIN, CRP
4
1.07
0.77
TJC, PATGL, FN, CRP
4
1.06
0.77
SJC, PAIN, PATGL, CRP
4
1.05
0.79
TJC, PAIN, FN, CRP
4
1.06
0.76
PAIN, PATGL, DOCGL, CRP
4
1.06
0.79
SJC, PAIN, DOCGL, ESR
4
1.05
0.79
SJC, PATGL, DOCGL, ESR
4
1.05
0.81
SJC, DOCGL, FN, ESR
4
1.04
0.80
TJC, PAIN, PATGL, CRP
4
1.03
0.75
SJC, PAIN, FN, ESR
4
1.01
0.75
TJC, DOCGL, FN, ESR
4
1.02
0.75
SJC, PATGL, FN, ESR
4
1.01
0.77
TJC, PATGL, DOCGL, ESR
4
1.02
0.76
TJC, PAIN, DOCGL, ESR
4
1.02
0.75
SJC, TJC, FN, ESR
4
0.99
0.72
SJC, TJC, DOCGL, ESR
4
1.00
0.75
SJC, TJC, PATGL, ESR
4
1.00
0.74
SJC, TJC, PAIN, ESR
4
1.00
0.72
PATGL, DOCGL, FN, ESR
4
1.01
0.78
PAIN, DOCGL, FN, ESR
4
1.01
0.77
SJC, PAIN, DOCGL, FN
4
0.99
0.72
SJC, PAIN, PATGL, ESR
4
0.98
0.74
SJC, PATGL, DOCGL, FN
4
0.99
0.73
PAIN, PATGL, FN, CRP
4
0.98
0.74
SJC, TJC, PAIN, DOCGL
4
0.97
0.69
SJC, TJC, PATGL, DOCGL
4
0.97
0.71
TJC, PAIN, FN, ESR
4
0.98
0.71
TJC, PATGL, FN, ESR
4
0.98
0.72
SJC, PAIN, PATGL, DOCGL
4
0.97
0.71
SJC, TJC, DOCGL, FN
4
0.96
0.69
PAIN, PATGL, DOCGL, ESR
4
0.98
0.75
TJC, PAIN, DOCGL, FN
4
0.96
0.68
SJC, TJC, PAIN, FN
4
0.94
0.66
TJC, PATGL, DOCGL, FN
4
0.96
0.70
SJC, TJC, PATGL, FN
4
0.94
0.67
TJC, PAIN, PATGL, ESR
4
0.96
0.70
SJC, TJC, PAIN, PATGL
4
0.93
0.66
TJC, PAIN, PATGL, DOCGL
4
0.95
0.68
SJC, PAIN, PATGL, FN
4
0.92
0.67
PAIN, PATGL, DOCGL, FN
4
0.92
0.68
TJC, PAIN, PATGL, FN
4
0.90
0.63
PAIN, PATGL, FN, ESR
4
0.90
0.68
SJC, FN, CRP
3
1.11
0.84
DOCGL, FN, CRP
3
1.12
0.86
SJC, PATGL, CRP
3
1.11
0.85
SJC, DOCGL, CRP
3
1.12
0.87
SJC, PAIN, CRP
3
1.10
0.83
PATGL, DOCGL, CRP
3
1.11
0.86
PAIN, DOCGL, CRP
3
1.11
0.84
TJC, DOCGL, CRP
3
1.10
0.82
TJC, FN, CRP
3
1.07
0.78
TJC, PATGL, CRP
3
1.07
0.79
SJC, TJC, CRP
3
1.05
0.77
TJC, PAIN, CRP
3
1.07
0.77
PATGL, FN, CRP
3
1.03
0.79
PAIN, FN, CRP
3
1.03
0.77
SJC, FN, ESR
3
1.00
0.77
SJC, DOCGL, ESR
3
1.02
0.80
SJC, PAIN, ESR
3
1.01
0.76
SJC, PATGL, ESR
3
1.01
0.79
DOCGL, FN, ESR
3
1.00
0.80
PATGL, DOCGL, ESR
3
1.02
0.80
PAIN, DOCGL, ESR
3
1.01
0.78
TJC, DOCGL, ESR
3
1.00
0.75
SJC, PAIN, DOCGL
3
0.99
0.72
PAIN, PATGL, CRP
3
0.99
0.74
SJC, PATGL, DOCGL
3
0.98
0.74
SJC, DOCGL, FN
3
0.97
0.72
TJC, FN, ESR
3
0.96
0.71
TJC, PATGL, ESR
3
0.98
0.73
SJC, TJC, ESR
3
0.95
0.70
TJC, PAIN, ESR
3
0.98
0.70
SJC, PAIN, FN
3
0.94
0.66
TJC, PATGL, DOCGL
3
0.95
0.70
TJC, PAIN, DOCGL
3
0.95
0.68
TJC, DOCGL, FN
3
0.94
0.68
SJC, PATGL, FN
3
0.93
0.68
SJC, TJC, PATGL
3
0.92
0.66
SJC, TJC, PAIN
3
0.92
0.64
SJC, TJC, DOCGL
3
0.93
0.67
PAIN, DOCGL, FN
3
0.94
0.69
PATGL, DOCGL, FN
3
0.94
0.70
SJC, PAIN, PATGL
3
0.91
0.66
SJC, TJC, FN
3
0.90
0.63
PATGL, FN, ESR
3
0.92
0.72
PAIN, FN, ESR
3
0.92
0.71
TJC, PAIN, FN
3
0.90
0.62
PAIN, PATGL, DOCGL
3
0.92
0.68
TJC, PATGL, FN
3
0.89
0.64
TJC, PAIN, PATGL
3
0.88
0.62
PAIN, PATGL, ESR
3
0.89
0.68
PAIN, PATGL, FN
3
0.83
0.60
SRMs: REFLEX: DAS28 = 1.04, CDAI = 0.92, and RAPID3 = 0.83; DANCER: DAS28 = 0.77, CDAI = 0.66, and RAPID3 = 0.6. Kruskal-Wallis values compare the changes from baseline to the last observation on or before week 24 between rituximab and placebo treatment. These -values were not adjusted for multiplicity. CRP: C-reactive protein; DOCGL: assessor global; ESR: erythrocyte sedimentation rate; FN: physical function; PAIN: pain; PATGL: patient global estimate; SJC: swollen joint count; TJC: tender joint count.
